Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients

被引:4
作者
Coleman, Craig I. [1 ]
Vaitsiakhovich, Tatsiana [2 ]
Nguyen, Elaine [3 ]
Weeda, Erin R. [4 ]
Sood, Nitesh A. [5 ]
Bunz, Thomas J. [6 ]
Schaefer, Bernhard [2 ]
Meinecke, Anna-Katharina [2 ]
Eriksson, Daniel [2 ]
机构
[1] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Storrs, CT 06269 USA
[2] Bayer AG, Real World Evidence Strategy & Outcomes Data Gene, Berlin, Germany
[3] Idaho State Univ, Coll Pharm, Dept Pharm Practice, Pocatello, ID 83209 USA
[4] Med Univ South Carolina, Coll Pharm, Dept Pharm Practice, Charleston, SC USA
[5] Southcoast Hlth Syst, Dept Cardiac Electrophysiol, Fall River, MA USA
[6] New England Hlth Analyt LLC, Pharmacoepidemiol, Granby, CT USA
关键词
Agreement; Anticoagulants; Atrial Fibrillation; Clinical Coding; Hemorrhage; REAL-WORLD EVIDENCE; UNITED-STATES; RIVAROXABAN; DABIGATRAN; APIXABAN; WARFARIN; SAFETY; STROKE; RISK;
D O I
10.1002/clc.22861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Schemas to identify bleeding-related hospitalizations in claims data differ in billing codes used and coding positions allowed. We assessed agreement across bleeding-related hospitalization coding schemas for claims analyses of nonvalvular atrial fibrillation (NVAF) patients on oral anticoagulation (OAC). Hypothesis: We hypothesized that prior coding schemas used to identify bleeding-related hospitalizations in claim database studies would provide varying levels of agreement in incidence rates. Methods: Within MarketScan data, we identified adults, newly started on OAC for NVAF from January 2012 to June 2015. Billing code schemas developed by Cunningham et al., the US Food and Drug Administration (FDA) Mini-Sentinel program, and Yao et al. were used to identify bleeding-related hospitalizations as a surrogate for major bleeding. Bleeds were subcategorized as intracranial hemorrhage (ICH), gastrointestinal (GI), or other. Schema agreement was assessed by comparing incidence, rates of events/100 person-years (PYs), and Cohen's kappa statistic. Results: We identified 151 738 new- users of OAC with NVAF (CHA2DS2-VASc score = 3, [interquartile range = 2-4] and median HAS-BLED score = 3 [interquartile range = 2-3]). The Cunningham, FDA Mini-Sentinel, and Yao schemas identified any bleeding-related hospitalizations in 1.87% (95% confidence interval [CI]: 1.81-1.94), 2.65% (95% CI: 2.57-2.74), and 4.66% (95% CI: 4.55-4.76) of patients (corresponding rates = 3.45, 4.90, and 8.65 events/100 PYs). Kappa agreement across schemas was weak-to-moderate (kappa = 0.47-0.66) for any bleeding hospitalization. Near-perfect agreement (kappa = 0.99) was observed with the FDA Mini-Sentinel and Yao schemas for ICH-related hospitalizations, but agreement was weak when comparing Cunningham to FDA Mini-Sentinel or Yao (kappa = 0.52-0.53). FDA Mini-Sentinel and Yao agreement was moderate (kappa = 0.62) for GI bleeding, but agreement was weak when comparing Cunningham to FDA Mini-Sentinel or Yao (kappa= 0.44-0.56). For other bleeds, agreement across schemas was minimal (kappa = 0.14-0.38). Conclusions: We observed varying levels of agreement among 3 bleeding-related hospitalizations schemas in NVAF patients.
引用
收藏
页码:119 / 125
页数:7
相关论文
共 24 条
[1]   Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study [J].
Abraham, Neena S. ;
Singh, Sonal ;
Alexander, G. Caleb ;
Heien, Herbert ;
Haas, Lindsey R. ;
Crown, William ;
Shah, Nilay D. .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[2]  
[Anonymous], TRICK 2 ALB RCTS RWE
[3]  
[Anonymous], EUR HEART J
[4]  
[Anonymous], PROTOCOL ASSESSMENT
[5]  
[Anonymous], MARKETSCAN RES DAT D
[6]   Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF [J].
Bassand, Jean-Pierre ;
Accetta, Gabriele ;
Camm, Alan John ;
Cools, Frank ;
Fitzmaurice, David A. ;
Fox, Keith A. A. ;
Goldhaber, Samuel Z. ;
Goto, Shinya ;
Haas, Sylvia ;
Hacke, Werner ;
Kayani, Gloria ;
Mantovani, Lorenzo G. ;
Misselwitz, Frank ;
ten Cate, Hugo ;
Turpie, Alexander G. G. ;
Verheugt, Freek W. A. ;
Kakkar, Ajay K. ;
Lucas Luciardi, Hector ;
Gibbs, Harry ;
Brodmann, Marianne ;
Pereira Barretto, Antonio Carlos ;
Connolly, Stuart J. ;
Spyropoulos, Alex ;
Eikelboom, John ;
Corbalan, Ramon ;
Hu, Dayi ;
Jansky, Petr ;
Nielsen, Jorn Dalsgaard ;
Ragy, Hany ;
Raatikainen, Pekka ;
Le Heuzey, Jean-Yves ;
Darius, Harald ;
Keltai, Matyas ;
Kakkar, Sanjay ;
Sawhney, Jitendra Pal Singh ;
Agnelli, Giancarlo ;
Ambrosio, Giuseppe ;
Koretsune, Yukihiro ;
Sanchez Diaz, Carlos Jerjes ;
Atar, Dan ;
Stepinska, Janina ;
Panchenko, Elizaveta ;
Lim, Toon Wei ;
Jacobson, Barry ;
Oh, Seil ;
Vinolas, Xavier ;
Rosenqvist, Marten ;
Steffel, Jan ;
Angchaisuksiri, Pantep ;
Oto, Ali .
EUROPEAN HEART JOURNAL, 2016, 37 (38) :2882-+
[7]   Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study [J].
Coleman, Craig I. ;
Antz, Matthias ;
Bowrin, Kevin ;
Evers, Thomas ;
Simard, Edgar P. ;
Bonnemeier, Hendrik ;
Cappato, Riccardo .
CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) :2047-2053
[8]   An automated database case definition for serious bleeding related to oral anticoagulant use [J].
Cunningham, Andrew ;
Stein, C. Michael ;
Chung, Cecilia P. ;
Daugherty, James R. ;
Smalley, Walter E. ;
Ray, Wayne A. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) :560-566
[9]  
Gandhi S.K., 1999, J MANAGE CARE PHARM, V5, P215, DOI DOI 10.18553/JMCP.1999.5.3.215
[10]   Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation [J].
Graham, David J. ;
Reichman, Marsha E. ;
Wernecke, Michael ;
Hsueh, Hui ;
Izem, Rima ;
Southworth, Mary Ross ;
Wei, Yuqin ;
Liao, Jiemin ;
Goulding, Margie R. ;
Mott, Katrina ;
Chillarige, Yoganand ;
MaCurdy, Thomas E. ;
Worrall, Chris ;
Kelman, Jeffrey A. .
JAMA INTERNAL MEDICINE, 2016, 176 (11) :1662-1671